Current clinical guidelines recommend the use of Glucagon-Like Peptide-1 (GLP-1) receptor agonists and SGLT-2 inhibitors in adults with type 2 diabetes and CKD to reduce cardiovascular risk and slow the progression of kidney disease, irrespective of glycemic control (92). Here, SLC5A2 is linked to kidney disorder.